The global microbubbles/ultrasound contrast agents market was valued at USD 1.02 billion in 2025. The market is estimated at USD 1.16 billion in 2026 and is projected to reach USD 4.35 billion by 2036, at a CAGR of 14.1% during the forecast period 2026-2036. This report provides a detailed assessment of the market, covering reimbursement and payment, regulatory labels and approved indications, clinical positioning, therapeutic microbubble applications, supply concentration, pricing, the competitive landscape, and future growth opportunities.
The market covers gas-filled microbubble contrast agents given intravenously to improve ultrasound imaging, along with their use in therapy. The bubbles are small enough to cross the lung circulation and stay inside the blood vessels, and because they resonate in an ultrasound field, they return a much stronger signal than tissue and make blood flow visible. The study covers lipid, protein, and polymer shell types, diagnostic and therapeutic uses, and hospitals, laboratories, and other care settings, and it separates agent revenue from ultrasound equipment and procedure revenue. Because the agent is a consumable used in a procedure on equipment the provider already owns, market economics are set largely by the economics of the procedure.
Payment, not clinical evidence, has been the main barrier to adoption in the largest national market, and that changed at the start of the forecast period. According to the 2026 coding and payment chart of the International Contrast Ultrasound Society, effective January 1, 2026, CPT 76978 for non-cardiac contrast-enhanced ultrasound of the initial lesion now falls in APC 5572 (Level 2 Imaging with Contrast), paid at USD 356.43 for hospital outpatients, the same class as contrast CT and MRI. According to the same chart, first-quarter 2026 average sales prices are USD 80.41 for a 2 mL Definity vial, USD 90.83 for a 5 mL Lumason vial, and USD 120.61 for a 3 mL Optison vial, and all three agents are separately payable. Lantheus Holdings reported that DEFINITY sales rose 6.8% to USD 84.6 million in the first quarter of 2026, while its total revenue grew 1.2%, showing growth specific to contrast ultrasound rather than to imaging in general.
Growth is held back by payment design for multi-lesion studies, as CPT 76979 for each additional lesion is bundled into hospital outpatient payment with no separate fee, though it is payable as an add-on outside the hospital. This limits the return on the complex cases where contrast-enhanced ultrasound adds most value. The technique also depends heavily on the operator: sonographers and radiologists must time image capture to the arrival and washout of the agent, read enhancement patterns, and use low mechanical index settings, so utilization varies widely between sites with the same equipment. Turning a payment change into working services is the central challenge, since each site needs a clinical sponsor, trained staff, protocols, and referral flow, and therapeutic forecasts risk overstating agent revenue because the bubble is a low-cost input to a costly device procedure.
The nearest opportunity lies in hospital departments that reviewed contrast-enhanced ultrasound before 2026 and declined it on cost; they already own the equipment, and the deciding factor has now changed. Pathway-based marketing to nephrology, obstetrics, and emergency medicine referrers can build durable demand among patients who cannot receive other contrast media, polymer and loadable formulations offer a route into therapeutic and theranostic use, and proven supply continuity helps a second agent enter departments that rely on one product. Key trends include payment for contrast ultrasound moving into line with contrast CT and MRI, the widening of the microbubble's role from imaging agent to therapeutic enabler, and agent franchises growing faster than the broader imaging businesses that own them.
By type, the microbubbles/ultrasound contrast agents market is segmented into lipid-shelled, protein-shelled, and polymer-shelled microbubbles. Lipid microbubbles hold the largest share in 2026, as a flexible lipid shell oscillates strongly at diagnostic pressures while staying stable in the bloodstream, giving the signal and persistence that imaging needs, and the agents with the broadest approved indications and the highest reported sales in cardiac and non-cardiac use are lipid-based. Polymer microbubbles are set to record the highest CAGR, not by displacing diagnostic agents but through therapeutic and sampling uses, because a stiffer polymer shell can carry a payload and be ruptured in a controlled way under focused ultrasound; this growth starts from a small base and depends on device-led pivotal trials. Protein microbubbles, built on human albumin, keep approved cardiac uses and a long echocardiography safety record and should grow in step with cardiac procedure volumes, although their plasma-derived raw material adds a sourcing consideration.
By application, the microbubbles/ultrasound contrast agents market is segmented into diagnostic imaging (cardiovascular, abdominal, renal, breast, and other imaging) and therapeutic applications (drug and gene delivery, blood brain barrier opening, sonobiopsy and biomarker sampling, and others). Diagnostic imaging accounts for the largest share in 2026, reflecting mature approved indications, a large installed ultrasound base in cardiology and radiology, and echocardiography as the highest-volume routine use. Therapeutic applications are set to grow at the highest CAGR, led by focused ultrasound techniques in which microbubbles briefly open the blood brain barrier to let drugs in or biomarkers out, both now in pivotal studies with regulatory designations, although the segment stays small in agent revenue because the bubble is a minor cost in a device-based procedure. Within diagnostic imaging, cardiovascular imaging leads on echocardiographic opacification, while abdominal imaging, mainly focal liver lesion characterization, grows the fastest following the payment reassignment, and renal imaging carries the strongest clinical rationale.
By end user, the microbubbles/ultrasound contrast agents market is segmented into hospitals & clinics, diagnostic laboratories, and other end users. Hospitals & clinics account for the largest share in 2026, as echocardiography and complex abdominal studies are concentrated in hospital departments, intravenous contrast use requires clinical governance and resuscitation capability, and the reassigned non-cardiac code sits within hospital outpatient payment. Diagnostic laboratories are set to post the highest CAGR, partly because the additional-lesion code is still paid as an add-on outside the hospital, which favors independent testing facilities for multi-lesion studies, and partly because a focused contrast ultrasound service runs at lower overhead outside a hospital. Other end users, including ambulatory surgical centers, specialty cardiology and hepatology practices, and academic research users, grow as diagnostic work moves out of acute hospitals.
North America holds the largest share of the global microbubbles/ultrasound contrast agents market in 2026, supported by the U.S. payment structure that now places the initial-lesion non-cardiac study in Level 2 Imaging with Contrast with the agent separately payable, the presence of the leading agent franchise, and an echocardiography base that supports the highest agent consumption of any market. Europe holds a strong position built on clinical practice and guideline leadership, as the region produced much of the evidence base and the enhancement criteria for focal lesion work, and contrast-enhanced ultrasound is more deeply embedded in hepatology and radiology there than in the U.S.; growth depends on national reimbursement decisions, which vary by country.
Asia-Pacific is set to grow at the highest CAGR, as contrast-enhanced ultrasound is widely accepted for liver lesion characterization in a region with a high burden of chronic liver disease, a perflubutane agent is approved in several national markets there though not in the U.S., and ultrasound is the main option where CT and MRI capacity per person is lower. In Latin America and the Middle East & Africa, the clinical case is strong because no extra capital equipment is needed and the agents are kidney-safe, but registration status and distribution reach vary by country and remain the main limits on access.
The microbubbles/ultrasound contrast agents market is highly concentrated, as three agents account for most global use and each is made by a single company. Diagnostic competition is therefore driven by indication breadth, clinical support, and supply reliability rather than price per dose, since a department prefers an agent labeled for the cases it plans to perform, trained sonographers and radiologists turn installed equipment into real utilization, and buyers committed to one agent face a continuity risk that at least one manufacturer cites as a business risk. Diversified contrast media and imaging groups compete alongside the agent specialists, while a separate group of therapeutic developers and focused ultrasound device companies treat microbubbles as a treatment enabler. In March 2022, for example, Insightec received FDA approval of two pivotal investigational device exemptions for Exablate Neuro, covering lung cancer brain metastases treated with pembrolizumab (with Breakthrough Device designation) and liquid biopsy in primary brain cancer.
Key companies profiled in the report include Lantheus Holdings, Inc. (U.S.), Bracco Imaging S.p.A. (Italy), GE HealthCare Technologies Inc. (U.S.), Daiichi Sankyo Company, Limited (Japan), Bayer AG (Germany), Insightec Ltd. (Israel), OxSonics Therapeutics Ltd (U.K.), Nuvox Pharma, LLC (U.S.), Trust Bio-sonics, Inc. (Taiwan), Cordance Medical, Inc. (U.S.), Advanced Microbubbles, Inc. (U.S.), and SonoThera, Inc. (U.S.).
The market covers gas-filled microbubble contrast agents given intravenously to improve ultrasound imaging, along with their use in therapy. The bubbles are small enough to cross the lung circulation and stay inside the blood vessels, and because they resonate in an ultrasound field, they return a much stronger signal than tissue and make blood flow visible. The study covers lipid, protein, and polymer shell types, diagnostic and therapeutic uses, and hospitals, laboratories, and other care settings, and it separates agent revenue from ultrasound equipment and procedure revenue. Because the agent is a consumable used in a procedure on equipment the provider already owns, market economics are set largely by the economics of the procedure.
Payment, not clinical evidence, has been the main barrier to adoption in the largest national market, and that changed at the start of the forecast period. According to the 2026 coding and payment chart of the International Contrast Ultrasound Society, effective January 1, 2026, CPT 76978 for non-cardiac contrast-enhanced ultrasound of the initial lesion now falls in APC 5572 (Level 2 Imaging with Contrast), paid at USD 356.43 for hospital outpatients, the same class as contrast CT and MRI. According to the same chart, first-quarter 2026 average sales prices are USD 80.41 for a 2 mL Definity vial, USD 90.83 for a 5 mL Lumason vial, and USD 120.61 for a 3 mL Optison vial, and all three agents are separately payable. Lantheus Holdings reported that DEFINITY sales rose 6.8% to USD 84.6 million in the first quarter of 2026, while its total revenue grew 1.2%, showing growth specific to contrast ultrasound rather than to imaging in general.
Market Dynamics
The main driver of the microbubbles/ultrasound contrast agents market in this period is the move of non-cardiac contrast-enhanced ultrasound to a higher outpatient payment level, which removes a financial disincentive and is expected to lift non-cardiac use early in the forecast rather than gradually. Demand is also supported by patients who cannot receive iodinated or gadolinium-based contrast: the agents carry no iodine or gadolinium, do not harm the kidneys or cross the placenta, and the exam uses no ionizing radiation, so for many patients with kidney disease or during pregnancy the alternative is no contrast study at all. Separate payment for the agent at average sales price means departments do not absorb the dose cost within the procedure fee, and therapeutic uses, in which microbubbles help deliver drugs or sample biomarkers, are drawing investment well ahead of revenue.Growth is held back by payment design for multi-lesion studies, as CPT 76979 for each additional lesion is bundled into hospital outpatient payment with no separate fee, though it is payable as an add-on outside the hospital. This limits the return on the complex cases where contrast-enhanced ultrasound adds most value. The technique also depends heavily on the operator: sonographers and radiologists must time image capture to the arrival and washout of the agent, read enhancement patterns, and use low mechanical index settings, so utilization varies widely between sites with the same equipment. Turning a payment change into working services is the central challenge, since each site needs a clinical sponsor, trained staff, protocols, and referral flow, and therapeutic forecasts risk overstating agent revenue because the bubble is a low-cost input to a costly device procedure.
The nearest opportunity lies in hospital departments that reviewed contrast-enhanced ultrasound before 2026 and declined it on cost; they already own the equipment, and the deciding factor has now changed. Pathway-based marketing to nephrology, obstetrics, and emergency medicine referrers can build durable demand among patients who cannot receive other contrast media, polymer and loadable formulations offer a route into therapeutic and theranostic use, and proven supply continuity helps a second agent enter departments that rely on one product. Key trends include payment for contrast ultrasound moving into line with contrast CT and MRI, the widening of the microbubble's role from imaging agent to therapeutic enabler, and agent franchises growing faster than the broader imaging businesses that own them.
Segment Analysis
The report analyzes the market by type, application, end user, and geography, helping stakeholders identify the most attractive areas for product development, service expansion, and investment.By type, the microbubbles/ultrasound contrast agents market is segmented into lipid-shelled, protein-shelled, and polymer-shelled microbubbles. Lipid microbubbles hold the largest share in 2026, as a flexible lipid shell oscillates strongly at diagnostic pressures while staying stable in the bloodstream, giving the signal and persistence that imaging needs, and the agents with the broadest approved indications and the highest reported sales in cardiac and non-cardiac use are lipid-based. Polymer microbubbles are set to record the highest CAGR, not by displacing diagnostic agents but through therapeutic and sampling uses, because a stiffer polymer shell can carry a payload and be ruptured in a controlled way under focused ultrasound; this growth starts from a small base and depends on device-led pivotal trials. Protein microbubbles, built on human albumin, keep approved cardiac uses and a long echocardiography safety record and should grow in step with cardiac procedure volumes, although their plasma-derived raw material adds a sourcing consideration.
By application, the microbubbles/ultrasound contrast agents market is segmented into diagnostic imaging (cardiovascular, abdominal, renal, breast, and other imaging) and therapeutic applications (drug and gene delivery, blood brain barrier opening, sonobiopsy and biomarker sampling, and others). Diagnostic imaging accounts for the largest share in 2026, reflecting mature approved indications, a large installed ultrasound base in cardiology and radiology, and echocardiography as the highest-volume routine use. Therapeutic applications are set to grow at the highest CAGR, led by focused ultrasound techniques in which microbubbles briefly open the blood brain barrier to let drugs in or biomarkers out, both now in pivotal studies with regulatory designations, although the segment stays small in agent revenue because the bubble is a minor cost in a device-based procedure. Within diagnostic imaging, cardiovascular imaging leads on echocardiographic opacification, while abdominal imaging, mainly focal liver lesion characterization, grows the fastest following the payment reassignment, and renal imaging carries the strongest clinical rationale.
By end user, the microbubbles/ultrasound contrast agents market is segmented into hospitals & clinics, diagnostic laboratories, and other end users. Hospitals & clinics account for the largest share in 2026, as echocardiography and complex abdominal studies are concentrated in hospital departments, intravenous contrast use requires clinical governance and resuscitation capability, and the reassigned non-cardiac code sits within hospital outpatient payment. Diagnostic laboratories are set to post the highest CAGR, partly because the additional-lesion code is still paid as an add-on outside the hospital, which favors independent testing facilities for multi-lesion studies, and partly because a focused contrast ultrasound service runs at lower overhead outside a hospital. Other end users, including ambulatory surgical centers, specialty cardiology and hepatology practices, and academic research users, grow as diagnostic work moves out of acute hospitals.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA), spanning 13 countries and three rest-of-region groups. The regional analysis of the microbubbles/ultrasound contrast agents market considers reimbursement structures, agent registration and availability, echocardiography and liver imaging practice, the burden of chronic liver and kidney disease, and access to CT and MRI capacity.North America holds the largest share of the global microbubbles/ultrasound contrast agents market in 2026, supported by the U.S. payment structure that now places the initial-lesion non-cardiac study in Level 2 Imaging with Contrast with the agent separately payable, the presence of the leading agent franchise, and an echocardiography base that supports the highest agent consumption of any market. Europe holds a strong position built on clinical practice and guideline leadership, as the region produced much of the evidence base and the enhancement criteria for focal lesion work, and contrast-enhanced ultrasound is more deeply embedded in hepatology and radiology there than in the U.S.; growth depends on national reimbursement decisions, which vary by country.
Asia-Pacific is set to grow at the highest CAGR, as contrast-enhanced ultrasound is widely accepted for liver lesion characterization in a region with a high burden of chronic liver disease, a perflubutane agent is approved in several national markets there though not in the U.S., and ultrasound is the main option where CT and MRI capacity per person is lower. In Latin America and the Middle East & Africa, the clinical case is strong because no extra capital equipment is needed and the agents are kidney-safe, but registration status and distribution reach vary by country and remain the main limits on access.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard, market share analysis, and benchmarking by approved indication breadth and supply continuity, together with company profiles of agent manufacturers and therapeutic microbubble developers.The microbubbles/ultrasound contrast agents market is highly concentrated, as three agents account for most global use and each is made by a single company. Diagnostic competition is therefore driven by indication breadth, clinical support, and supply reliability rather than price per dose, since a department prefers an agent labeled for the cases it plans to perform, trained sonographers and radiologists turn installed equipment into real utilization, and buyers committed to one agent face a continuity risk that at least one manufacturer cites as a business risk. Diversified contrast media and imaging groups compete alongside the agent specialists, while a separate group of therapeutic developers and focused ultrasound device companies treat microbubbles as a treatment enabler. In March 2022, for example, Insightec received FDA approval of two pivotal investigational device exemptions for Exablate Neuro, covering lung cancer brain metastases treated with pembrolizumab (with Breakthrough Device designation) and liquid biopsy in primary brain cancer.
Key companies profiled in the report include Lantheus Holdings, Inc. (U.S.), Bracco Imaging S.p.A. (Italy), GE HealthCare Technologies Inc. (U.S.), Daiichi Sankyo Company, Limited (Japan), Bayer AG (Germany), Insightec Ltd. (Israel), OxSonics Therapeutics Ltd (U.K.), Nuvox Pharma, LLC (U.S.), Trust Bio-sonics, Inc. (Taiwan), Cordance Medical, Inc. (U.S.), Advanced Microbubbles, Inc. (U.S.), and SonoThera, Inc. (U.S.).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the microbubbles/ultrasound contrast agents market at global, regional, and country levels.
- Explains how moving non-cardiac contrast-enhanced ultrasound into a higher U.S. payment class in 2026 changes adoption economics.
- Assesses the impact of multi-lesion payment packaging, operator dependence, and training needs on service growth.
- Identifies high-growth opportunities across type, application, end user, and region.
- Tracks therapeutic uses such as blood brain barrier opening, drug and gene delivery, and sonobiopsy, and explains why their value accrues mainly to devices.
- Benchmarks agent manufacturers and therapeutic developers by indication breadth, supply continuity, and strategic developments.
- Supports product planning, market access, service development, partnering, and investment decisions for agent manufacturers, device developers, providers, and investors.
Key Questions Answered
- How big is the microbubbles/ultrasound contrast agents market worldwide today, and how will it grow through 2036?
- How will the 2026 change in U.S. hospital outpatient payment affect non-cardiac contrast-enhanced ultrasound volumes?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- Why is demand among patients with renal impairment or pregnancy resistant to substitution by other modalities?
- Which types, applications, and end users will grow the fastest?
- How large can therapeutic microbubble applications become, and how much of their value goes to agent makers?
- How does supply concentration affect provider sourcing and competition among agents?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading companies, and how do they compare on indication breadth, clinical support, and supply reliability?
Table of Contents
1. Market Definition & Scope
2. Research Methodology
3. Executive Summary
4. Market Insights
5. Global Microbubbles/Ultrasound Contrast Agents Market Assessment, by Type
6. Global Microbubbles/Ultrasound Contrast Agents Market Assessment, by Application
7. Global Microbubbles/Ultrasound Contrast Agents Market Assessment, by End User
8. Global Microbubbles/Ultrasound Contrast Agents Market Assessment, by Geography
9. Competition Analysis
10. Company Profiles
11. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Lantheus Holdings, Inc.
- Bracco Imaging S.p.A.
- GE HealthCare Technologies Inc.
- Daiichi Sankyo Company, Limited
- Bayer AG
- Insightec Ltd.
- OxSonics Therapeutics Ltd
- Nuvox Pharma, LLC
- Trust Bio-sonics, Inc.
- Cordance Medical, Inc.
- Advanced Microbubbles, Inc.
- SonoThera, Inc.
